Biopharma Portfolio Optimization and Board Risk Analysis
Prioritize a biopharma portfolio with value modeling, correlation, downside risk, stage-gate logic and explicit scenarios.
Decision questions
What this solution is built to answer.
Which assets deserve scarce capital relative to the rest of the portfolio?
Where is value concentrated, correlated, or exposed to the same biological or regulatory risk?
What changes under downside, payer, delay, or competitor-entry stress scenarios?
Which programs should move from investigate to go, hold, or kill?
Science and method
What can change the model or gate.
Portfolio value aggregation from per-asset valuation outputs.
Correlation matrices and concentration-risk views across therapeutic area, mechanism, stage, and modality.
Downside distribution analysis from Monte Carlo simulations.
Portfolio optimization under budget and risk constraints.
Framework reconciliation across GE-McKinsey, BCG, stage-gate, three-horizons, and real-options logic.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| portfolio-quickscreen | Fast triage with Go / Investigate / Hold / Kill verdicts | PORTFOLIO__TRIAGE_SUMMARY and scoring matrix |
| portfolio-optimization | Efficient frontier, scenarios, real options, and resource allocation | PORTFOLIO__BOARD_DOSSIER, stress tornado, resource heatmap |
| portfolio-strategic-prioritization | Board-grade prioritization across strategic frameworks | Strategic dossier and board recommendation |
| valuation-professional-workflow | Portfolio valuation layer | VALUATION__PORTFOLIO, correlation matrix, risk pack, professional report |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Portfolio triage table with confidence gates.
Portfolio value and downside-risk pack.
Efficient-frontier and resource-allocation visuals.
Board dossier with explicit recommendations and caveats.
Proof points
The strategy workflows include Go / Investigate / Hold / Kill language instead of forcing false certainty.
Portfolio valuation and portfolio strategy are separate but composable surfaces.
Optimization can incorporate risk constraints rather than ranking by upside only.
Limits and review conditions
What this result does not establish.
An optimized allocation reflects the stated objective, constraints and correlation assumptions; it does not remove strategic judgment.
FAQ
Common evaluation questions.
Does portfolio optimization only rank assets?
Ranking is one output. ARiDA also stages evidence, calculates portfolio value and risk, models constraints, and produces decision artifacts for leadership review.
Can the portfolio be revisited after new data?
Yes. The platform is built around persistent sessions, files, and workflow artifacts, so follow-up runs can update the existing case rather than starting from scratch.
Related solutions
Biotech Valuation
Connect scientific evidence and uncertainty to PoS, rNPV, option value and the asset or portfolio decision under review.
Real Options Analysis
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Competitive Intelligence
Build competitive landscapes, TPP comparisons, patent-cliff views, market-share scenarios, and response plans from live web, trial, patent, literature, and database evidence.
Related reading
Triage a portfolio without turning judgment into a score
Use hard gates, uncertainty and resource constraints to expose the real allocation choice.
Build the decision case before the committee deck
A committee document is credible only when the evidence, assumptions and alternatives exist underneath it.
Parallel work matters only when the decision record survives
Specialists can divide a complex review, but the result needs one controlled case and a clear release state.